What is the official website of QPharma, Inc. ?

The official website of QPharma, Inc. is http://www.qpharmacorp.com.

What is QPharma, Inc.'s cybersecurity risk score?

QPharma, Inc. has an AI-generated cybersecurity risk score of 695 out of 1000, indicating a Weak security posture according to Rankiteo's assessment.

How many security incidents has QPharma, Inc. experienced?

According to Rankiteo, QPharma, Inc. currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has QPharma, Inc. been affected by any supply chain cyber incidents ?

According to Rankiteo, QPharma, Inc. has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does QPharma, Inc. have SOC 2 Type 1 certification ?

According to Rankiteo, QPharma, Inc. is not certified under SOC 2 Type 1.

Does QPharma, Inc. have SOC 2 Type 2 certification ?

According to Rankiteo, QPharma, Inc. does not hold a SOC 2 Type 2 certification.

Does QPharma, Inc. comply with GDPR ?

According to Rankiteo, QPharma, Inc. is not listed as GDPR compliant.

Does QPharma, Inc. have PCI DSS certification ?

According to Rankiteo, QPharma, Inc. does not currently maintain PCI DSS compliance.

Does QPharma, Inc. comply with HIPAA ?

According to Rankiteo, QPharma, Inc. is not compliant with HIPAA regulations.

Does QPharma, Inc. have ISO 27001 certification ?

According to Rankiteo,QPharma, Inc. is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does QPharma, Inc. operate in ?

QPharma, Inc. operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does QPharma, Inc. have ?

QPharma, Inc. employs approximately 161 people worldwide.

Does QPharma, Inc. own any subsidiaries ?

QPharma, Inc. presently has no subsidiaries across any sectors.

How many LinkedIn followers does QPharma, Inc. have ?

QPharma, Inc.'s official LinkedIn profile has approximately 17,242 followers.

What is the NAICS classification code for QPharma, Inc. ?

QPharma, Inc. is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does QPharma, Inc. have a Crunchbase profile ?

No, QPharma, Inc. does not have a profile on Crunchbase.

Does QPharma, Inc. have a LinkedIn profile ?

Yes, QPharma, Inc. maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/qpharma-inc.

How many cybersecurity incidents has QPharma, Inc. experienced ?

As of August 3, 2026, Rankiteo reports that QPharma, Inc. has experienced 1 cybersecurity incidents.

How many peer or competitor companies does QPharma, Inc. have ?

QPharma, Inc. has an estimated 5,720 peer or competitor companies worldwide.

What types of cybersecurity incidents has QPharma, Inc. faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

QPharma, Inc.

Boost Score +25 with badge (5 left)

695

/1000

Weak

720

/1000

Moderate

QPharma, Inc. Vendor Cyber Rating & Cyber Score

qpharmacorp.com

Add Your Compliance Badge

Founded in 1994, QPharma is the industry leader in cloud-based software and services for life sciences. The Commercial Services division provides solutions that include sample management and distribution, product launch management, online training, and HCP/KOL targeting and engagement. Services offered by the company’s Professional Services division include validation services, project management, auditing, and training. QPharma is a National Association of Boards of Pharmacy Verified Accredited Wholesale Distributor, and an approved American Medical Association Database Licensee. To learn more, visit www.qpharmacorp.com.

QPharma, Inc. A.I CyberSecurity Scoring

Scoring History

QPharma, Inc.

QPharma, Inc. CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

QPharma, Inc.

Breach

12/2024

QPH514072525

Loading…

A.I.

QPharma, Inc. Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for QPharma, Inc.

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for QPharma, Inc. in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for QPharma, Inc. in 2026.

Incident Types QPharma, Inc. vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for QPharma, Inc. in 2026.

Incident History - QPharma, Inc. (X = Date, Y = Severity)

Loading…

SUBSIDIARY

QPharma, Inc. Subsidiaries

QPharma, Inc.

Pharmaceutical Manufacturing

Website: http://www.qpharmacorp.com

Company Size: 201-500 employees

QPharma CareersPharmaceutical Manufacturing

Loading…

QPharma, Inc. Similar Companies

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Loading…

NEWS

QPharma, Inc. CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-18577

SUMMARY

An incomplete patch for CVE-2026-18556 allows for authentication bypass and account takeover in N-central Versions through 2026.3.1

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:L/SI:L/SA:L/E:A/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-10848

SUMMARY

The OCPP 1.6 client in subsys/net/lib/ocpp parsed inbound WAMP RPC frames in parse_rpc_msg() (subsys/net/lib/ocpp/ocpp_j.c) using a hand-rolled helper, extract_string_field(), that copied the message's uid and action fields with strncpy(out_buf, token + 1, outlen - 1) and then scanned the result with strchr(out_buf, '"'). Because strncpy does not NUL-terminate the destination when the source is at least outlen - 1 (127) bytes long, the subsequent strchr reads past the 128-byte destination buffer into adjacent stack memory; if a " byte is found beyond the buffer, a one-byte out-of-bounds NUL write also occurs. A related defect in extract_payload() runs strchr/strrchr over the receive buffer, which may not be NUL-terminated when a maximal-length frame fills it. The parsed bytes come directly from the OCPP central-system server over a websocket: the reader thread fills recv_buf via websocket_recv_msg() and calls parse_rpc_msg() on each inbound DATA frame (subsys/net/lib/ocpp/ocpp.c). A malicious or compromised central server, or an on-path attacker (OCPP is commonly deployed over plain ws://), can send an RPC frame whose uid or action field is 127+ bytes with no closing quote, triggering the out-of-bounds access. The primary impact is a remotely triggerable denial of service: the unbounded scan can fault on an unmapped page, and the stray NUL write can corrupt adjacent stack state. The over-read data is not reflected to the peer, so disclosure is limited. The feature is EXPERIMENTAL and must be explicitly enabled (CONFIG_OCPP). The fix replaces the manual parser with the bounds-respecting json_mixed_arr_parse() and copies the extracted uid with an explicitly NUL-terminated buffer, eliminating both over-reads.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 7)

cvss3

Base Score: 7.0

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:L/A:H

Impact Score

4.7

Exploitability

2.2

REFERENCES

CVE-2026-9856

SUMMARY

A vulnerability in huggingface/transformers versions <=5.8.0.dev0 allows an attacker to perform arbitrary file writes via path traversal. The issue resides in the `save_pretrained()` methods of `PreTrainedTokenizerBase` and `ProcessorMixin`, where keys from the `chat_template` dictionary are used directly as filenames without proper validation. An attacker can exploit this by publishing a malicious Hugging Face Hub repository with a crafted `tokenizer_config.json` file. When a victim downloads and saves the tokenizer or processor, the attacker-controlled keys can escape the intended save directory, enabling arbitrary file writes with attacker-controlled content. This vulnerability affects multiple processors inheriting from `ProcessorMixin`, including Idefics, Florence, Gemma, Phi, and Qwen-VL.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.0/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:H/A:L

Impact Score

4.2

Exploitability

2.8

REFERENCES

CVE-2026-65321

SUMMARY

PyAthena prior to 3.35.4 contains a sql injection vulnerability that allows unauthenticated attackers to inject arbitrary SQL by exploiting improper quote-escaping in DefaultParameterFormatter.format(), which routes DELETE and CTAS statements to the _escape_hive function that backslash-escapes single quotes rather than doubling them. Because Athena and Trino do not treat backslashes as escape characters inside string literals, attacker-supplied input such as a single quote followed by SQL syntax causes the parser to terminate the string literal prematurely, enabling data exfiltration via UNION SELECT, execution of destructive statements, and attacker-controlled CTAS destination and content.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-10774

SUMMARY

Zephyr's Bluetooth Mesh subnet key management leaks one PSA Crypto key slot on every subnet-key teardown. In subsys/bluetooth/mesh/subnet.c, net_keys_create() imports the Private Beacon Key into a PSA key slot under CONFIG_BT_MESH_PRIV_BEACONS (enabled by default), but subnet_keys_destroy() guarded the matching psa_destroy_key() with CONFIG_BT_MESH_V1d1. That Kconfig symbol was removed when explicit Mesh 1.0.1 support was dropped, so the destroy branch became permanently dead code and the import is never balanced by a destroy. The imbalanced teardown is reached every time subnet keys are destroyed: deleting a subnet (Config Server NetKey Delete), completing a Key Refresh Procedure (which retires the old key set), and resetting/re-provisioning the node. The over-the-air triggers are processed only under the node's device key, so they are exercisable by the provisioner or network administrator that owns the node, reachable over the Bluetooth Mesh network. With the default CONFIG_MBEDTLS_PSA_KEY_SLOT_COUNT of 16, repeated add/delete or key-refresh cycles exhaust the shared PSA key-slot pool after roughly a dozen rounds. Once exhausted, bt_mesh_private_beacon_key() and thus subnet creation fail: the node can no longer add subnets or complete key refresh, and other PSA crypto consumers on the device may be starved, until the device is rebooted. The fix aligns the destroy guard with the import guard (CONFIG_BT_MESH_PRIV_BEACONS) so each slot is freed.

Published

Date2026-08-02

Updated

Date2026-08-02

RISK INFORMATION (Score: 2.4)

cvss3

Base Score: 2.4

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:H/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

0.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…